The HealthGene BRAF PCR Test is a highly sensitive molecular diagnostic assay designed to detect the BRAF V595E mutation in canine urine samples. This mutation is present in a large proportion of canine urothelial carcinomas (transitional cell carcinomas) and prostatic carcinomas, making it an important molecular biomarker for the evaluation of dogs with lower urinary tract disease.
Using real-time Polymerase Chain Reaction (PCR) technology, the assay identifies tumor-associated DNA that is naturally shed into urine, providing a non-invasive alternative to surgical biopsy in many patients. The test assists veterinarians in differentiating neoplastic disease from inflammatory or infectious urinary tract conditions while supporting earlier diagnosis and more informed clinical decision-making.
Lower urinary tract diseases often present with similar clinical signs regardless of the underlying cause. Dogs with urinary tract infections, bladder stones, chronic cystitis, and urothelial carcinoma may all exhibit hematuria, dysuria, pollakiuria, or urinary obstruction.
Because these conditions frequently overlap clinically, diagnosis based on clinical signs alone can be challenging.
The HealthGene BRAF PCR Test provides a molecular approach to identifying dogs that may have urothelial or prostatic carcinoma by detecting a cancer-associated genetic mutation directly from urine.
Early molecular detection may support:
The BRAF gene encodes a protein kinase that plays an essential role in regulating normal cell growth, differentiation, and survival through the MAPK (Mitogen-Activated Protein Kinase) signaling pathway.
In many canine urothelial and prostatic carcinomas, a specific mutation known as BRAF V595E causes continuous activation of this pathway, leading to uncontrolled cellular proliferation and tumor development.
The HealthGene assay specifically detects this clinically significant mutation in DNA released from tumor cells into the urine.
Cancer cells originating within the urinary tract continuously shed DNA into urine.
The HealthGene BRAF PCR Test isolates DNA from the submitted urine sample and uses real-time PCR technology to determine whether the BRAF V595E mutation is present.
Because tumor DNA may be detected without obtaining tissue biopsies, molecular testing provides a convenient and minimally invasive diagnostic option for many patients.
The BRAF PCR Test is recommended for dogs presenting with:
*Clinical interpretation for monitoring should always be performed in conjunction with the patient's clinical history and imaging findings.
Consider BRAF PCR in dogs presenting with:
The HealthGene BRAF PCR Test offers several advantages over traditional diagnostic approaches:
✓ Non-invasive urine-based testing
✓ Highly specific detection of the BRAF V595E mutation
✓ Rapid turnaround time
✓ Supports earlier identification of urothelial carcinoma
✓ Assists in differentiating neoplasia from inflammatory urinary disease
✓ May reduce the need for invasive biopsy in appropriate clinical cases
✓ Complements diagnostic imaging, cytology, and histopathology
Real-time PCR directly detects tumor-associated genetic mutations rather than relying solely on cytologic interpretation or imaging findings.
Molecular testing provides:
Although abdominal ultrasound, radiography, cystoscopy, cytology, and histopathology remain important diagnostic tools, each provides different information.
The HealthGene BRAF PCR Test complements these methods by adding molecular evidence of neoplastic disease.
| Diagnostic Method | Information Provided |
|---|---|
| Urinalysis | Detects inflammation, infection, crystals, and hematuria |
| Urine Culture | Identifies bacterial urinary tract infections |
| Ultrasound | Evaluates bladder wall, masses, and regional anatomy |
| Cytology | Examines cellular morphology when neoplastic cells are present |
| Histopathology | Confirms tumor type through tissue evaluation |
| BRAF PCR | Detects the BRAF V595E mutation associated with canine urothelial and prostatic carcinoma |
A positive BRAF PCR result indicates detection of the BRAF V595E mutation, supporting the presence of a mutation-positive urothelial or prostatic carcinoma.
A negative result does not completely exclude neoplasia. Not all urothelial carcinomas carry the BRAF mutation, and molecular findings should always be interpreted alongside the patient's clinical presentation, imaging studies, cytology, and other diagnostic findings.
The HealthGene BRAF PCR Test detects the BRAF V595E mutation only.
Some urothelial carcinomas do not harbor this mutation and therefore may produce negative PCR results despite the presence of malignancy.
For dogs with persistent clinical suspicion and negative BRAF results, additional diagnostic evaluation—including imaging, cytology, histopathology, or expanded molecular testing (where available)—may be appropriate.
The assay is recommended for dogs with persistent lower urinary tract signs, recurrent urinary tract infections, unexplained hematuria, bladder masses, or suspected urothelial or prostatic carcinoma.
The BRAF PCR Test provides valuable molecular evidence supporting the diagnosis of mutation-positive urothelial and prostatic carcinoma. However, histopathology may still be required in selected cases to establish tumor type, grade, or when additional pathological evaluation is necessary.
No. A negative result indicates that the BRAF V595E mutation was not detected in the submitted sample. Because not all canine urothelial carcinomas harbor this mutation, additional diagnostic testing may still be warranted when clinical suspicion remains high.
The HealthGene BRAF PCR Test combines advanced molecular diagnostics with the convenience of non-invasive urine sampling to support the evaluation of canine lower urinary tract disease. By detecting the clinically significant BRAF V595E mutation, the assay provides veterinarians with objective molecular information that complements conventional diagnostics and assists in the early investigation of urothelial and prostatic carcinoma.
